Ganetespib (STA-9090) Monotherapy in Untreated Metastatic HER2+/TNBC

  • Research type

    Research Study

  • Full title

    An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy In Women With Previously Untreated Metastic HER2 Positive Or Triple Negative Breast Cancer



  • Contact name

    David Cameron

  • Contact email

  • Sponsor organisation

    Synta Pharmaceuticals Corp.

  • Eudract number


  • Identifier


  • Research summary

    This study aims to investigate ganetespib (STA-9090) as a potential new anti-cancer therapy. Ganetespib is a small chemical that binds to, and inhibits a protein called Hsp90. Hsp90 is essential to the activity of certain other proteins (called growth factors) that drive the growth, proliferation, and survival of different types of cancer cells. By inhibiting Hsp90, ganetespib causes the degradation of these downstream growth factors, resulting in the subsequent degradation of cancer cells dependent upon these growth factors. This study aims to evaluate the effectiveness of ganetespib, as a 2nd line treatment, in women with either metastatic HER2 positive, or Triple Negative Breast Cancer (TNBC); patients with these breast cancer subtypes have poor prognosis??s in comparison to patients with other breast cancer subtypes. In clinical trials to date, researchers have seen encouraging preliminary laboratory research of ganetespib treatment for these indications. Results from this study will be used to guide the further development of ganetespib therapy in metastatic breast cancer.

  • REC name

    West of Scotland REC 1

  • REC reference


  • Date of REC Opinion

    25 Jul 2012

  • REC opinion

    Further Information Favourable Opinion